MRI-based parameters and clinical risk factors to predict lymph node metastasis in patients with ypT0 rectal cancer after neoadjuvant chemoradiotherapy

被引:0
|
作者
Wang, Yangyang [1 ,2 ]
Wang, Xiaojie [2 ]
Huang, Shenghui [2 ]
Chen, Jinhua [3 ]
Huang, Ying [2 ]
机构
[1] Shandong First Med Univ, Affiliated Hosp 2, Dept Gastrointestinal Surg, Tai An, Peoples R China
[2] Fujian Med Univ, Union Hosp, Dept Colorectal Surg, Fuzhou, Fujian, Peoples R China
[3] Fujian Med Univ, Union Hosp, Follow Up Ctr, Fuzhou, Fujian, Peoples R China
关键词
clinical complete remission; lymph node metastasis; neoadjuvant chemoradiotherapy; rectal-preserving strategy; LOCAL EXCISION; ORGAN PRESERVATION; TUMOR RESPONSE; OPEN-LABEL; FOLLOW-UP; CHEMORADIATION; OUTCOMES; MULTICENTER; ANEMIA; SIZE;
D O I
10.1111/ans.18876
中图分类号
R61 [外科手术学];
学科分类号
摘要
Backgrounds: The aim of this study was to assess the significant risk factors that predict lymph node metastasis in ypT0 patients with locally advanced rectal cancer following chemoradiotherapy (CRT). Additionally, the study aimed to identify high-risk groups who would not be suitable candidates for a rectal-preserving strategy, despite achieving a complete tumour response.Methods: Between 2013 and 2021, 226 ypT0 patients with stages II/III rectal cancer underwent CRT and radical surgery were enrolled. Two groups of patients were evaluated: those with lymph nodes metastasis and those without. The selection of variables for multivariable logistic regression was conducted through bivariate logistic regression analysis. Furthermore, the determination of optimal cutoff values for risk factors was achieved using ROC curve analysis.Results: Nearly 8% (18/226) of patients with ypT0 had positive lymph nodes (LN) on final pathology. Four variables resulted as being independent factors of LN metastasis: pre-CRT tumour movability (OR = 8.618, P = 0.003), pre-CRT maximal LN size (OR = 28.474, P = 0.004), post-CRT tumour vertical length (OR = 1.492, P = 0.050), post-CRT anaemia (OR = 10.288, P = 0.001). The optimal cutoff point of pre-CRT maximal LN size and post-CRT tumour vertical length was 7.50 mm and 3.05 cm, respectively.Conclusion: The prevalence of lymph node metastasis remains at 8% among patients who achieve pathological complete regression of the primary tumour. In instances where patients are considered appropriate candidates for a rectal-preserving strategy after clinical complete remission, careful consideration should be given to the selection of this strategy if specific risk factors are present. These risk factors encompass a maximal LN size surpassing 7.50 mm prior to CRT, a fixed tumour prior to CRT, a tumour vertical length exceeding 3.05 cm after CRT, and the existence of anaemia subsequent to CRT.
引用
收藏
页码:1127 / 1132
页数:6
相关论文
共 50 条
  • [1] Clinicopathological factors predict residual lymph node metastasis in locally advanced rectal cancer with ypT0-2 after neoadjuvant chemoradiotherapy
    Cui, Yujun
    Song, Maxiaowei
    Tie, Jian
    Li, Shuai
    Wang, Hongzhi
    Zhang, Yangzi
    Geng, Jianhao
    Liu, Zhiyan
    Teng, Huajing
    Sui, Xin
    Zhu, Xianggao
    Cai, Yong
    Li, Yongheng
    Wang, Weihu
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (04)
  • [2] Long-term outcomes in patients with ypT0 rectal cancer after neoadjuvant chemoradiotherapy and curative resection
    Lu, Zhao
    Cheng, Pu
    Yang, Fu
    Zheng, Zhaoxu
    Wang, Xishan
    CHINESE JOURNAL OF CANCER RESEARCH, 2018, 30 (02) : 272 - 281
  • [3] Clinicopathological characteristics predict lymph node metastases in ypT0-2 rectal cancer after chemoradiotherapy
    Bosch, Steven L.
    Vermeer, Thomas A.
    West, Nicholas P.
    Swellengrebel, Hendrik A. M.
    Marijnen, Corrie A. M.
    Cats, Annemieke
    Verhoef, Cornelis
    van Lijnschoten, Ineke
    de Wilt, Johannes H. W.
    Rutten, Harm J.
    Nagtegaal, Iris D.
    HISTOPATHOLOGY, 2016, 69 (05) : 839 - 848
  • [4] Prognostic factors in patients with complete response of the tumour (ypT0) after neoadjuvant chemoradiotherapy and radical resection of rectal cancer
    Zhang, Hang
    Sun, Ge
    Zheng, Kuo
    Lou, Zheng
    Gao, Xian H.
    Meng, Rong G.
    Furnee, Edgar J. B.
    Zhang, Wei
    ANZ JOURNAL OF SURGERY, 2021, 91 (04) : E190 - E195
  • [5] Oncologic Outcome After Preoperative Chemoradiotherapy in Patients With Pathologic T0 (ypT0) Rectal Cancer
    Jang, Tae Young
    Yu, Chang Sik
    Yoon, Yong Sik
    Lim, Seok-Byung
    Hong, Seung-Mo
    Kim, Tae Won
    Kim, Jong Hoon
    Kim, Jin Cheon
    DISEASES OF THE COLON & RECTUM, 2012, 55 (10) : 1024 - 1031
  • [6] Long-term outcomes in patients with ypT0 rectal cancer after neoadjuvant chemoradiotherapy and curative resection
    Zhao Lu
    Pu Cheng
    Fu Yang
    Zhaoxu Zheng
    Xishan Wang
    ChineseJournalofCancerResearch, 2018, 30 (02) : 272 - 281
  • [7] Multiparametric MRI-based radiomic model for predicting lymph node metastasis after neoadjuvant chemoradiotherapy in locally advanced rectal cancer
    Wei, Qiurong
    Chen, Ling
    Hou, Xiaoyan
    Lin, Yunying
    Xie, Renlong
    Yu, Xiayu
    Zhang, Hanliang
    Wen, Zhibo
    Wu, Yuankui
    Liu, Xian
    Chen, Weicui
    INSIGHTS INTO IMAGING, 2024, 15 (01):
  • [8] Comparative Analysis of Lymph Node Metastases in Patients With ypT0-2 Rectal Cancers After Neoadjuvant Chemoradiotherapy
    Park, In Ja
    You, Y. Nancy
    Skibber, John M.
    Rodriguez-Bigas, Miguel A.
    Feig, Barry
    Nguyen, Sa
    Hu, Chung-Yuan
    Chang, George J.
    DISEASES OF THE COLON & RECTUM, 2013, 56 (02) : 135 - 141
  • [9] The role of adjuvant chemotherapy in rectal cancer patients with ypT0-2N0 after neoadjuvant chemoradiotherapy
    Yang, Jianguo
    Deng, Qican
    Chen, Zhenzhou
    Chen, Yajun
    Fu, Zhongxue
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [10] A nomogram prediction model for lymph node metastasis risk after neoadjuvant chemoradiotherapy in rectal cancer patients based on SEER database
    Liu, Xiaoshuang
    Sha, Li
    Huang, Cheng
    Kong, Xiancheng
    Yan, Feihu
    Shi, Xiaohui
    Tang, Xuefeng
    FRONTIERS IN ONCOLOGY, 2023, 13